67th Day Of Lockdown

Maharashtra62228269972098 Tamil Nadu2024611313157 Delhi173877846398 Gujarat159448611980 Rajasthan83654855184 Madhya Pradesh76454410334 Uttar Pradesh74454215201 West Bengal48131775302 Bihar3359120915 Andhra Pradesh3330223460 Karnataka278189448 Telangana2256134567 Punjab2197194942 Jammu and Kashmir216487528 Odisha17239779 Haryana172194019 Kerala11515659 Assam9361044 Uttarakhand493794 Jharkhand4621914 Chandigarh3641894 Chhatisgarh364830 Tripura2421650 Himachal Pradesh223634 Goa68370 Puducherry49170 Meghalaya20121 Nagaland1800 Manipur540 Arunachal Pradesh210 Mizoram110 Sikkim100
Business Other News 13 May 2020 Gilead ties up with ...

Gilead ties up with Hetero drugs, 4 other generic drugmakers for Covid19 drug supply

REUTERS
Published May 13, 2020, 8:37 am IST
Updated May 13, 2020, 10:54 am IST
The licenses are royalty-free until the World Health Organization declares the end of the public health emergency regarding Covid-19
Gilead Sciences Inc said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan. (Photo- Twitter)
 Gilead Sciences Inc said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan. (Photo- Twitter)

Gilead Sciences Inc said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.

The pacts allow the companies - Jubilant Life Sciences Ltd, Cipla Ltd, Hetero Labs Ltd, Mylan NV and Ferozsons Laboratories Ltd-to make and sell the drug in 127 countries.

 

The countries consist of nearly all low-income and lower-middle income ones, as well as several that are upper-middle- and high-income, the drugmaker said. Afghanistan, India, North Korea, Pakistan and South Africa are among the countries.

The licensees will also set their own prices for the generic product they produce, Gilead said.

The licenses are royalty-free until the World Health Organization declares the end of the public health emergency regarding COVID-19, or until a product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, the company said.

Gilead’s antiviral drug remdesivir earlier this month received the US Food and Drug Administration’s emergency use authorization to treat COVID-19 patients.

With no other approved treatment for COVID-19, the respiratory illness caused by the novel coronavirus, interest in remdesivir has been growing, and the company is being closely watched on the pricing and distribution of the limited supply of the drug.

Gilead last week said it was negotiating long-term licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing countries and that it would provide technology to aid the production.

The pandemic has killed nearly 286,000 people globally, according to a Reuters tally, and several drugmakers are racing to develop a viable treatment or vaccine to combat the outbreak.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT